arrow
A

Alessandro Parisi

università politecnica delle marche
H指数:22
被引数:2,087

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
MAP of molecular analyses in real-worlD oncology centers – MAPpaMoNDO: a study of the translational research Young GOIM group

现实世界肿瘤中心分子分析地图——MAPpaMoNDO:青年GOIM组转化研究的研究

2026-08-180
OA
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience

关于免疫治疗时代接受多模式治疗的晚期胆道癌患者的初步报告:一项真实世界多中心经验

2026-03-190
OA
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors

临床可解释的 nomogram 结合体成分和临床病理特征,用于预测晚期实体瘤患者一年生存率

2026-03-120
OAAI
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Real-world management and long-term outcomes in adolescent, young adult, and adult medulloblastoma: Experience from a monocentric series with multimodal and targeted approaches

真实世界的管理和长期结局:青少年、青年和成人髓母细胞瘤的多模式及靶向治疗单中心系列研究经验

2025-11-010
PRE
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY

短期放疗用于局部晚期直肠癌且不适合化疗的老年患者:SOFT研究

2025-10-250
PRE
Beyond Molecular Characterization: The Impact of Age-Adjusted Charlson Comorbidity Index in Glioblastoma Patients Treated with Radio or Radio-Chemotherapy

超越分子表征:年龄调整的Charlson合并症指数在经放疗或放化疗治疗的胶质母细胞瘤患者中的影响

2025-10-230
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity

10年来血液病患者的病毒性呼吸道感染:流行病学及其对疾病严重程度的影响

2025-10-010
PRE
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study

伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗:LEVIATHAN 研究

2025-09-230
OAAI
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE